Promising Developments in Maze Therapeutics’ Pipeline: Buy Rating Reinforced by MZE829 and MZE782 Advances

In a report released today, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on Maze Therapeutics, Inc., with a price target of $50.00.

Ananda Ghosh’s rating is based on the promising developments in Maze Therapeutics’ dual-asset pipeline, particularly focusing on MZE829 and MZE782. The presentations at the ASN Kidney Week 2025 reinforced confidence in these assets, with MZE829 showing potential as a treatment for CKD driven by APOL1 variants, which are significant in both diabetic and non-diabetic populations. The mechanistic evidence supporting the reversal of podocyte toxicity further bolsters the outlook for MZE829 ahead of its pivotal Phase 2 HORIZON readout in early 2026.
Ananda Ghosh also highlights the genetic validation of MZE782, which targets SLC6A19 variants known to delay CKD progression. This positions MZE782 as a potential first-in-class therapy for PKU and CKD. The robust target engagement data and the anticipated Phase trials in 2026 contribute to the positive sentiment. Overall, the upcoming clinical milestones and the potential for significant share price appreciation underpin Ghosh’s Buy rating for Maze Therapeutics.